Anthem Bioscienc Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 6 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹50.1K Cr
Anthem Biosciences expects steady growth with a historical CAGR of around 20% year-on-year, maintaining this outlook for FY25 vs FY26 and beyond. Anthem Biosciences targets steady margins in EBITDA, gross margin, and PAT margin levels, maintaining around 38% EBITDA margin as seen in FY25.
From Anthem Bioscienc's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹871
Market Cap
₹50.1K Cr
P/E Ratio
84.5
How does Anthem Bioscienc rank in Pharmaceuticals & Biotechnology?
Compare Anthem Bioscienc against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Anthem Bioscienc — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹611 Cr, net profit ₹190 Cr.
Full financials →📊 Revenue & Sales Performance
- →Anthem Biosciences expects steady growth with a historical CAGR of around 20% year-on-year, maintaining this outlook for FY25 vs FY26 and beyond.
- →Growth is driven largely by commercialized molecules, with multiple products seeing increased demand across several clients.
- →There is significant headroom for growth across existing commercial products, but sales volumes may not increase every quarter due to customer stocking patterns.
- →The company plans capacity expansions ahead of demand to support future growth, anticipating customers’ needs and new modalities.
- →Development-stage products and new modalities like peptides and ADCs will contribute to growth over multiple years, though with longer gestation and smaller volumes initially.
- →Growth in CRO (Contract Research Organization) segment is expected to be driven by adding scientific talent and expanding lab capacities.
- →Customer expansion includes both innovators and emerging biotech, with no significant pricing pressure currently anticipated.
📈 Profitability & Margins
- →Anthem Biosciences targets steady margins in EBITDA, gross margin, and PAT margin levels, maintaining around 38% EBITDA margin as seen in FY25.
- →The company anticipates about 20% CAGR growth in revenues year-on-year for FY26 and beyond, consistent with its historical performance.
- →Growth drivers include increased demand for commercial products and capacity expansions in custom synthesis and fermentation.
- →Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth.
- →New product segments like GLP-1 peptides are expected to be exciting growth drivers over the next 2-3 years.
- →Management is cautiously optimistic, preferring to wait on upcoming quarters before updating outlook but remains confident in medium-term growth.
- →EBITDA and gross margins expected to remain steady without significant fluctuations.
🏗️ Capital Expenditure Plans
- →Anthem Biosciences is undertaking capacity expansion with a capital commitment of about INR 150 crores to complete Unit 2 and Unit 3 commissioning.
- →Unit 4 expansion is in early planning stage; detailed plans and capex numbers will be shared once finalized.
- →Expansion funding will primarily come from internal accruals and existing net cash balance of about INR 785 crores.
- →The company has recently commissioned 54 kiloliters of custom synthesis capacity in Q1 FY26; balance 76 kiloliters to be added by end of calendar year.
- →Additional 25 kiloliters peptide synthesis capacity built in NeoAnthem unit as part of custom synthesis expansion.
- →An additional 40 kiloliters of fermentation capacity is being added at NeoAnthem, expected to complete in calendar year.
- →Anthem follows a strategy of investing ahead of demand to avoid capacity shortages and seize growth opportunities.
💰 Fundraising & Capital Structure
- →Anthem Biosciences currently holds about INR 785 crores of net cash.
- →The company plans to deploy a large portion of this cash towards capacity expansion (units 2, 3, and 4).
- →Unit 4 is in early planning stages, and detailed capital expenditure plans will be shared once finalized.
- →Management indicated that if attractive borrowing rates are available, they would consider taking on debt.
- →However, the company aims to maintain a positive net cash position and prefers funding expansions primarily through internal accruals/net cash.
- →No specific announcements of new fundraising through debt or equity have been made as of now.
📋 Order Book & Pipeline
- →Anthem Biosciences has multiple ongoing projects with clients, both in development and commercialization stages, indicating a robust order book.
- →The company works with global pharmaceutical companies and handles several late-stage Phase 3 molecules, some moving to commercialization.
- →They have around 10 molecules in Phase 3 as of March 2025, with 2 recently approved and commercialized, indicating active project pipeline.
- →Anthem is also involved in lateral projects and becoming a second source for existing products, adding to their pending order prospects.
- →Capacity expansions (units 2, 3, and upcoming unit 4) are aligned with the expected growth in order volumes.
- →Management has emphasized multi-year, multi-product engagements with clients, suggesting committed order flow over coming years.
- →The company expects continued demand from established commercial molecules and projects under development to steadily contribute to revenues.
Key Metrics
Frequently Asked Questions
What were Anthem Bioscienc Q1 FY26 results?
Anthem Biosciences expects steady growth with a historical CAGR of around 20% year-on-year, maintaining this outlook for FY25 vs FY26 and beyond. Anthem Biosciences targets steady margins in EBITDA, gross margin, and PAT margin levels, maintaining around 38% EBITDA margin as seen in FY25.
What is Anthem Bioscienc share price analysis?
Anthem Bioscienc currently shows a neutral. The stock trades at a P/E of 84.5 with a market cap of ₹50,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anthem Bioscienc planning capital expenditure?
Anthem Biosciences is undertaking capacity expansion with a capital commitment of about INR 150 crores to complete Unit 2 and Unit 3 commissioning.
Keep Anthem Bioscienc on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.